ID   HCT 116 AXL KO Tet-inducible
AC   CVCL_HG04
DR   Wikidata; Q54881912
DR   Ximbio; 153206
RX   PubMed=24170546;
CC   Knockout cell: Method=shRNA knockdown; HGNC; 905; AXL.
CC   Sequence variation: Homozygous for ACVR2A p.Lys437Argfs*5 (c.1310delA) (dbSNP=rs764719749) (from parent cell line).
CC   Sequence variation: Heterozygous for BRCA2 p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA) (ClinVar=VCV000267050) (from parent cell line).
CC   Sequence variation: Heterozygous for CDKN2A p.Arg24fs*20 (c.68_69insG) and p.Glu74fs*15 (c.220delG) (from parent cell line).
CC   Sequence variation: Heterozygous for CTNNB1 p.Ser45del (c.133_135delTCT) (ClinVar=VCV000017576) (from parent cell line).
CC   Sequence variation: Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (from parent cell line).
CC   Sequence variation: Heterozygous for PIK3CA p.His1047Arg (c.3140A>G) (ClinVar=VCV000013652) (from parent cell line).
CC   Sequence variation: Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (ClinVar=VCV000477546) (from parent cell line).
CC   Derived from sampling site: Colon.
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0291 ! HCT 116
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 29-10-20; Version: 7
//
RX   PubMed=24170546; DOI=10.1158/1078-0432.CCR-13-1354;
RA   Dunne P.D., McArt D.G., Blayney J.K., Kalimutho M., Greer S., Wang T.,
RA   Srivastava S., Ong C.W., Arthur K., Loughrey M., Redmond K.L.,
RA   Longley D.B., Salto-Tellez M., Johnston P.G., Van Schaeybroeck S.;
RT   "AXL is a key regulator of inherent and chemotherapy-induced invasion
RT   and predicts a poor clinical outcome in early-stage colon cancer.";
RL   Clin. Cancer Res. 20:164-175(2014).
//